Randomised controlled trial

Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients

N Engl J MedPublished

  • Randomised controlled trial
  • double-blind
  • placebo-controlled

Authors' conclusion

Among statin-intolerant patients, treatment with bempedoic acid was associated with a lower risk of major adverse cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization).

Study context

Population
Statin-intolerant patients with, or at high risk for, CVD
Participants
13,970 participants
Comparison
Bempedoic acid vs placebo
  • Bempedoic acidn = 6,992
  • Placebon = 6,978reference
Primary endpoint
MACE: death from CV causes, nonfatal MI, nonfatal stroke or coronary revascularization

Primary result

As reported in the abstract

Hazard ratio

0.87

95% CI 0.79–0.96

P = 0.004

Events by treatment group

Bempedoic acid vs Placebo
HR 0.87 (95% CI 0.79–0.96); P = 0.004

Further findings

OutcomeBempedoic acidPlaceboHR (95% CI)P value
Death from CV causes, nonfatal stroke or nonfatal MI8.2%9.5%0.85 (0.76–0.96)P = 0.006
Fatal or nonfatal MI3.7%4.8%0.77 (0.66–0.91)P = 0.002
Coronary revascularization6.2%7.6%0.81 (0.72–0.92)P = 0.001
Outcomedifference (mg per deciliter)P value
LDL-C reduction vs placebo · 6 months29.2
  • LDL-C reduction vs placebo: difference in percent reductions 21.1 percentage points; baseline mean 139.0 mg per deciliter in both groups

Fatal or nonfatal stroke, death from CV causes, death from any cause

No significant effects

Safety

Gout

Cholelithiasis

Small increases in serum creatinine, uric acid and hepatic-enzyme levels

Higher incidence with bempedoic acid than placebo

Original publication

Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med. Published 4 March 2023. doi:10.1056/nejmoa2215024

Summarised from the published abstract; every number is checked against it